KRW 40 bil JAKi market is in a fierce three-way race
By Kim, Jin-Gu | translator Kim, Jung-Ju
24.02.06 12:09:53
가나다라
0
Last year’s prescription sales rank Olumiant KRW 13.7 bil > > Xeljanz KRW 13.3 bil > Rinvoq 12.4 bil
Olumiant leads the market in Q2-Q3 last year...Rinvoq tops the market in Q4
Xeljanz’s sales in a downward trend since 2021...Civinqo-Jyseleca start their chase
▲(Clockwise) Jyseleca, Civinqo, Rinvoq, Olumiant, Xeljanz 제품사진.
The competition is intensifying leadership in the Janus kinase (JAK) inhibitor market, an oral autoimmune disease treatment, in Korea.
Lilly's Olumiant (baricitinib) became the market leader in Q2 last year, as sales of the longtime leader Pfizer's Xeljanz (tofacitinib) faltered. Then, in just 2 quarters, AbbVie's Rinvoq (upadacitinib) took over the lead.
In addition, new drugs such as Pfizer's Civinqo (abrocitinib) and Eisai’s Jyseleca (filgotinib) have also been introduced to the market. This is why the pharmaceutical industry is competing to further intensify in the JAK inhibitor market.
JAK inhibitor market amounts to KRW 40 bil last year…Rinvoq’s sales s
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)